{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T08:25:47Z","timestamp":1722414347882},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00280-010-1414-x","type":"journal-article","created":{"date-parts":[[2010,7,31]],"date-time":"2010-07-31T16:21:22Z","timestamp":1280593282000},"page":"231-236","source":"Crossref","is-referenced-by-count":8,"title":["Effects of methimazole on the elimination of irinotecan"],"prefix":"10.1007","volume":"67","author":[{"given":"Jessica M.","family":"van der Bol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo J.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter J.","family":"Loos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floris A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik A. C.","family":"Wiemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten O.","family":"van Aken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre S.","family":"Planting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,1]]},"reference":[{"key":"1414_CR1","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2001.19.5.1501","volume":"19","author":"U Vanhoefer","year":"2001","unstructured":"Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM (2001) Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 19:1501\u20131518","journal-title":"J Clin Oncol"},{"key":"1414_CR2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/157488406778249307","volume":"1","author":"A Di Paolo","year":"2006","unstructured":"Di Paolo A, Bocci G, Danesi R, Del Tacca M (2006) Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. Curr Clin Pharmacol 1:311\u2013323","journal-title":"Curr Clin Pharmacol"},{"key":"1414_CR3","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","volume":"27","author":"F Innocenti","year":"2009","unstructured":"Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ (2009) Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27:2604\u20132614","journal-title":"J Clin Oncol"},{"key":"1414_CR4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ejca.2007.12.012","volume":"44","author":"FA Jong de","year":"2008","unstructured":"de Jong FA, Sparreboom A, Verweij J, Mathijssen RH (2008) Lifestyle habits as a contributor to anti-cancer treatment failure. Eur J Cancer 44:374\u2013382","journal-title":"Eur J Cancer"},{"key":"1414_CR5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/94.16.1247","volume":"94","author":"RH Mathijssen","year":"2002","unstructured":"Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A (2002) Effects of St. John\u2019s wort on irinotecan metabolism. J Natl Cancer Inst 94:1247\u20131249","journal-title":"J Natl Cancer Inst"},{"key":"1414_CR6","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1200\/JCO.2006.09.6115","volume":"25","author":"JM Bol van der","year":"2007","unstructured":"van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, van Schaik RH, de Jonge MJ, Planting AS, Verweij J, Sparreboom A, de Jong FA (2007) Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 25:2719\u20132726","journal-title":"J Clin Oncol"},{"key":"1414_CR7","first-page":"390","volume":"25","author":"Z Guo","year":"1997","unstructured":"Guo Z, Raeissi S, White RB, Stevens JC (1997) Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos 25:390\u2013393","journal-title":"Drug Metab Dispos"},{"key":"1414_CR8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF02738878","volume":"4","author":"TJ Visser","year":"1996","unstructured":"Visser TJ, Kaptein E, Gijzel A, de Herder WW, Cannon ML, Bonthuis F, de Greef WJ (1996) Effects of thyroid status and thyrostatic drugs on hepatic glucuronidation of lodothyronines and other substrates in rats. Endocrine 4:78\u201385","journal-title":"Endocrine"},{"key":"1414_CR9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ab.2004.01.007","volume":"328","author":"P Bruijn de","year":"2004","unstructured":"de Bruijn P, Willems EW, Loos WJ, Verweij J, Sparreboom A (2004) Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples. Anal Biochem 328:84\u201386","journal-title":"Anal Biochem"},{"key":"1414_CR10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0378-4347(98)00147-9","volume":"712","author":"A Sparreboom","year":"1998","unstructured":"Sparreboom A, de Bruijn P, de Jonge MJ, Loos WJ, Stoter G, Verweij J, Nooter K (1998) Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr B Biomed Sci Appl 712:225\u2013235","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"1414_CR11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/hep.1840090225","volume":"9","author":"W Steenbergen Van","year":"1989","unstructured":"Van Steenbergen W, Fevery J, De Vos R, Leyten R, Heirwegh KP, De Groote J (1989) Thyroid hormones and the hepatic handling of bilirubin. I. Effects of hypothyroidism and hyperthyroidism on the hepatic transport of bilirubin mono- and diconjugates in the Wistar rat. Hepatology 9:314\u2013321","journal-title":"Hepatology"},{"key":"1414_CR12","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.2002.08.177","volume":"20","author":"DF Kehrer","year":"2002","unstructured":"Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A (2002) Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 20:3122\u20133129","journal-title":"J Clin Oncol"},{"key":"1414_CR13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-005-0053-0","volume":"57","author":"PJ Tobin","year":"2006","unstructured":"Tobin PJ, Beale P, Noney L, Liddell S, Rivory LP, Clarke S (2006) A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemother Pharmacol 57:309\u2013316","journal-title":"Cancer Chemother Pharmacol"},{"key":"1414_CR14","first-page":"3752","volume":"56","author":"K Takasuna","year":"1996","unstructured":"Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752\u20133757","journal-title":"Cancer Res"},{"key":"1414_CR15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s002800050818","volume":"42","author":"K Takasuna","year":"1998","unstructured":"Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1998) Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42:280\u2013286","journal-title":"Cancer Chemother Pharmacol"},{"key":"1414_CR16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1067\/mcp.2002.126741","volume":"72","author":"R Xie","year":"2002","unstructured":"Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO (2002) Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 72:265\u2013275","journal-title":"Clin Pharmacol Ther"},{"key":"1414_CR17","first-page":"1136","volume":"7","author":"DF Kehrer","year":"2001","unstructured":"Kehrer DF, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, Ruijgrok EJ, de Jonge MJ (2001) Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7:1136\u20131141","journal-title":"Clin Cancer Res"},{"key":"1414_CR18","first-page":"1157","volume":"25","author":"JG Slatter","year":"1997","unstructured":"Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC (1997) Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 25:1157\u20131164","journal-title":"Drug Metab Dispos"},{"key":"1414_CR19","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.1158\/1078-0432.CCR-05-0703","volume":"11","author":"WP Yong","year":"2005","unstructured":"Yong WP, Ramirez J, Innocenti F, Ratain MJ (2005) Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res 11:6699\u20136704","journal-title":"Clin Cancer Res"},{"key":"1414_CR20","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","volume":"104","author":"H Burger","year":"2004","unstructured":"Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump. Blood 104:2940\u20132942","journal-title":"Blood"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1414-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T23:56:40Z","timestamp":1551571000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1414-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1414"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1414-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,1]]}}}